Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma-Reference-Cited by-同舟云学术

Constitutive Canonical NF-κB Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma

Published:2010-12 Issue:6 Volume:18 Page:580-589
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Calado Dinis Pedro,Zhang Baochun,Srinivasan Lakshmi,Sasaki Yoshiteru,Seagal Jane,Unitt Christine,Rodig Scott,Kutok Jeffery,Tarakhovsky Alexander,Schmidt-Supprian Marc,Rajewsky Klaus

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference37 articles.

1. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling;Alizadeh;Nature,2000

2. Commitment of B lymphocytes to a plasma cell fate is associated with Blimp-1 expression in vivo;Angelin-Duclos;J. Immunol.,2000

3. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma;Annunziata;Cancer Cell,2007

4. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma;Banham;Clin. Cancer Res.,2005

5. Constitutive CD40L expression on B cells prematurely terminates germinal center response and leads to augmented plasma cell production in T cell areas;Bolduc;J. Immunol.,2010

Cited by 173 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. B cells secrete functional antigen-specific IgG antibodies on extracellular vesicles;Scientific Reports;2024-07-23

2. The genomic and molecular landscape of splenic marginal zone lymphoma, biological and clinical implications;Exploration of Targeted Anti-tumor Therapy;2024-07-23

3. Advances in biology, diagnosis and treatment of DLBCL;Annals of Hematology;2024-07-17

4. Notch2 controls developmental fate choices between germinal center and marginal zone B cells upon immunization;Nature Communications;2024-03-04

5. Development of Potent MALT1 Inhibitors Featuring a Novel “2-Thioxo-2,3-dihydrothiazolo[4,5-d]pyrimidin-7(6H)-one” Scaffold for the Treatment of B Cell Lymphoma;Journal of Medicinal Chemistry;2024-02-13